Community-Acquired Bacterial Pneumonia Market Poised for Expansion Through 2036 Amid Rising Antimicrobial Resistance
核心洞察
The community-acquired bacterial pneumonia (搜索) (CABP) treatment market is expected to grow positively by 2036 across the United States, EU4, the United Kingdom, and Japan, with the U.S. holding the largest share in 2025.
Around 80% of the nearly 4 million community-acquired pneumonia (搜索) cases in the U.S. are classified as CABP, underscoring the substantial burden of bacterial pathogens.
Emerging Phase II candidates CAL02, AON-D21, and Trimodulin (BT588) target bacterial virulence factors and host inflammatory responses to complement conventional antibiotics.
The community-acquired bacterial pneumonia (搜索) (CABP) treatment market is poised for continued growth through 2036, driven by a substantial global disease burden, increasing hospitalization rates, an aging population, rising prevalence of comorbidities, and the growing challenge of antimicrobial resistance. According to a recently published market insights report from DelveInsight, the launch of emerging therapies such as CAL02 (Eagle Pharmaceutical/Combioxin (搜索)), AON-D21 (APTARION Biotech (搜索)), and Trimodulin (BT588; Biotest AG (搜索)) is expected to further propel market expansion across the leading markets of the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Disease Burden and Market Dynamics
Community-acquired pneumonia (搜索) (CAP) continues to represent a substantial global health burden, contributing significantly to both morbidity and mortality. Around 80% of the nearly 4 million cases of CAP in the U.S. are classified as CABP, highlighting the significant burden of bacterial pathogens in pneumonia cases. In the U.S., mild cases of CABP constituted the highest proportion—approximately 50% of total incident cases—followed by moderate cases at around 35%.
The United States accounted for the largest CABP treatment market size in the 7MM in 2025, compared to other major markets including the EU4 countries, the United Kingdom, and Japan. The total CABP treatment market size is expected to grow positively by 2036 in these leading markets.
Drivers of Market Growth
Several factors are fueling demand for effective CABP treatment options. The persistent incidence of CABP, particularly among older adults, children, and individuals with underlying conditions, continues to drive the need for new therapies, with associated morbidity, hospitalization rates, and mortality further supporting market growth.
The growing prevalence of antibiotic-resistant bacterial pathogens is creating a need for novel antibiotics and therapies with improved efficacy against resistant strains, encouraging pharmaceutical companies to invest in next-generation antibacterial treatments. Ongoing research into novel antibacterial mechanisms, improved formulations, and targeted therapies is expanding the treatment landscape, potentially providing additional options for patients who have limited responses to conventional antibiotics.
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, noted that emerging candidates such as CAL02 and AON-D21 are being developed to complement conventional antibiotic treatment by targeting bacterial toxins, virulence factors, and host inflammatory responses. "These novel approaches aim to improve clinical outcomes in severe CABP and address challenges associated with antimicrobial resistance and treatment failure," Thakur said.
Current Treatment Landscape
Identifying the optimal antibiotic therapy for CAP remains challenging due to several clinical and epidemiological considerations. The treatment landscape is evolving as the efficacy and safety profiles of established antibiotics change over time, and the growing prevalence of antimicrobial resistance has further complicated treatment decisions by reducing the effectiveness of previously reliable therapies against certain pathogens. Clinicians must carefully select antibiotic regimens based on local resistance trends, suspected causative pathogens, disease severity, and individual patient characteristics.
The introduction of newer antibiotics has expanded therapeutic options for CAP in recent years. Agents such as omadacycline (NUZYRA), delafloxacin (BAXDELA), and lefamulin (XENLETA) have strengthened the CAP treatment armamentarium, particularly for patients who are unsuitable for or do not adequately respond to conventional therapies. Several antibiotics are also approved for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), including cefiderocol (FETROJA), ceftazidime-avibactam (AVYCAZ), telavancin (VIBATIV), and the combination of ceftolozane and tazobactam (ZERBAXA).
Commonly used antimicrobial regimens include macrolides, either alone or in combination with β-lactams; amoxicillin as monotherapy or combined with a macrolide; fluoroquinolones; and third-generation cephalosporins administered in combination with a macrolide. By comparison, the pipeline for emerging therapies specifically targeting CAP remains relatively limited.
Emerging Pipeline Candidates
Eagle Pharmaceutical/Combioxin (搜索)'s CAL02 is a Phase II-stage therapeutic candidate being developed to address severe infections, particularly CAP among critically ill ICU patients. The treatment consists of liposomes formulated with cholesterol and sphingomyelin, with sphingomyelin incorporated for its distinctive anti-infective properties, highlighting the therapeutic potential of antimicrobial lipids in combating bacterial infections.
CAL02 works by neutralizing bacterial virulence effectors, which play a significant role in the development of organ dysfunction and life-threatening complications associated with severe infections. By targeting these virulence mechanisms rather than solely focusing on bacterial eradication, CAL02 aims to limit disease progression and potentially improve clinical outcomes. The candidate has received Fast Track and Qualified Infectious Disease Product (QIDP) designations from the U.S. FDA, which can provide an additional five years of market exclusivity, potentially extending the total exclusivity period to eight or ten years.
APTARION Biotech (搜索)'s AON-D21 is another therapeutic candidate currently undergoing Phase II clinical development. It is a PEGylated, L-configured aptamer—a synthetic molecule engineered to selectively bind to specific biological targets. AON-D21 is designed to modulate the complement pathway by selectively binding to and neutralizing C5a (搜索), a key component of the immune system. C5a serves as an important mediator of immune activity and plays a central role in coordinating inflammatory responses, creating opportunities for C5a-targeted therapies across multiple disease areas, particularly conditions in which excessive or dysregulated immune responses contribute to disease progression.
The anticipated launch of these emerging therapies is poised to transform the CABP market landscape in the coming years. As these therapies continue to mature and gain regulatory approval, they are expected to reshape the CABP market, offering new standards of care and unlocking opportunities for medical innovation and economic growth.